Vascular
embolization provides an effective approach for the treatment
of hemorrhage, aneurysms, and other vascular abnormalities. However,
current embolic materials, such as metallic coils and liquid embolic
agents, are limited by their inability to provide safe, consistent,
and controlled embolization. Here, we report an injectable hydrogel
that can remain at the injection site and subsequently undergo in
situ covalent crosslinking, leading to the formation of a dual-crosslinking
network (DCN) hydrogel for endovascular embolization. The DCN hydrogel
is simple to prepare, easy to deploy via needles and catheters, and
mechanically stable at the target injection site, thereby avoiding
embolization of nontarget vessels. It possesses efficient hemostatic
activity and good biocompatibility. The DCN hydrogel is also clearly
visible under X-ray imaging, thereby allowing for targeted embolization.
In vivo tests in a rabbit artery model demonstrates that the DCN hydrogel
is effective in achieving immediate embolization of the target artery
with long-term occlusion by inducing luminal fibrosis. Collectively,
the DCN hydrogel provides a viable, biocompatible, and cost-effective
alternative to existing embolic materials with clinical translation
potential for endovascular embolization.